Dechra Pharmaceuticals, founded in 1997 following a management buy-out from Lloyds Chemists, develops prescription only veterinary medicines for dogs, cats and horses. Most of its projects involve adapting treatments, currently used by humans, for the animal market. Expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. It listed in London in 2000.
Dechra Pharmaceuticals Plc Ord 1P is listed on the London Stock Exchange trading with ticker code DPH.L, and is part of the Medicine and Biotech Research sector. It has a market capitalisation of £260,736m, with approximately 102m shares in issue.
Dechra Pharmaceuticals Plc, officially known as Dechra Pharmaceuticals Plc Ord 1P was formed in May of 1997, making the company twenty two years old. The company filed its latest accounts on 30th June 2015, showing a turnover of approximately 203.48 million GBX with gross profits of 116.14 million, or 1.1350 per issued share, and a pre-tax profit margin of 12.68%. Dechra Pharmaceuticals Plc currently has 7 directors, and has had 14 previous directors over the last 22 years. In the last set of accounts produced by Kpmg Llp, the company showed 45.61 million paid in salaries to the 863 staff (average wage of 53 thousand), with the directors receiving an average 546 thousand each. In the accounts filed in 2015, the company paid 13857000 in dividends, or 0.1354 per share. These accounts also showed Dechra Pharmaceuticals Plc to have a net worth of 27.80 million, with 45.95 million held in cash.
Dechra Pharmaceuticals Plc is in the Medicine and Biotech Research sector.
|Qinetiq Group Plc (QQ..L)|
|Hikma Pharmaceuticals Plc (HIK.L)|
|Serco Group Plc (SRP.L)|
|Jpmorgan American Investment Trust Plc (JAM.L)|
|Wetherspoon ( J.d.) Plc (JDW.L)|
|Shares in Issue||102m|
|52 Week High||0.00|
|52 Week Low||0.00|